Competitive inhibitor of HMG-CoA reductase.
 Decrease relative risk of heart attack and stroke.
 JUPITER TRIAL (2008) suggested rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia but with elevated levels of highly sensitive C-reactive protein.